Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. METHODS: In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. RESULTS: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. CONCLUSIONS: Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045 · cited 2×
“These included the VABS (Sparrow et al. 1984) and the Children’s Yale-Brown Obsessive Compulsive Scale Modified for PDD (CY-BOCS-PDD) (Scahill et al. 1997, 2006).”
MethodSelf-citationRisperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citationCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 4×
“The higher percentage of children with excessive appetite (42%) is consistent with the literature and with weight gain findings in other studies (Martin et al. 2004; Aman et al. 2005a; Correll et al. 2009; Hellings et al. 2010).”
BackgroundResultInfluentialUse of psychotropic medication in children and adolescents with autism spectrum disorders
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0900d · Cited by 191 · cited 2×
“The use of psychotropic medications as one component of treatment for children with autism spectrum disorder (ASD) has grown rapidly, with surveys indicating that * 50% of individuals with ASD take psychotropic drugs or supplements intended to address impairing behaviors (Aman et al. 2005b; Coury et al. 2012).”
BackgroundMedication Patterns in Patients with Autism: Temporal, Regional, and Demographic Influences
Aman, M. G., Lam, K. S. L., & Van Bourgondien, M. E. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.116 · Cited by 174
Self-citationMarcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Aman, M. G. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0121 · Cited by 82 · cited 3×
“Similarly, a 52 week follow-up of aripiprazole for irritability in autism reported that only 60% completed the naturalistic study and many required the addition of concomitant medications (Marcus et al. 2011a).”
BackgroundResultSelf-citationLack of effect of risperidone on core autistic symptoms: data from a longitudinal study
Marrus, N., Underwood-Riordan, H., Randall, F., Zhang, Y., & Constantino, J. N. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0055 · Cited by 29 · cited 1×
“Marrus et al. (2014) obtained serial parent-rated Social Responsiveness Scale (SRS) ratings from children treated with risperidone for mean durations of 4.4–5.2 years (depending on the type of comparison obtained).”
BackgroundInfluential
Research works printed but not linked: 34
- 10.1089/cap.2005.15.869 · DOI · Paper page
- Aman MG, 1985, Am J Ment Deficiency, 89, 485
- Aman MG, 1985, Am J Mental Deficiency, 89, 492
- Aman MG, 1987, Am J Ment Deficiency, 92, 237
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders
- 10.1023/A:1005451304303 · DOI
- Bozkurt H, 2011, Arch Neuropsychiatry, 48, 164
- 10.1097/00004583-199706000-00022 · DOI · Paper page
- 10.1037/0033-2909.112.1.155 · doi:10.1037/0033-2909.112.1.155 · Paper page
- 10.1089/cap.2011.0071 · doi:10.1089/cap.2011.0071
- 10.1016/S0002-7138(09)60610-5 · DOI
- Ghanizadeh A, 2008, Prim Psychiatry, 15, 32
- 10.1097/01.CHI.0000046842.56865.EC · DOI
- 10.1097/01.CHI.0000046841.56865.37 · DOI
- 10.1358/dot.2003.39.7.799445 · DOI · Paper page
- 10.1080/19315864.2010.494763 · DOI
- 10.1089/cap.2006.0056 · DOI
- 10.1089/cap.2012.0058 · DOI
- 10.1177/0883073810382143 · DOI · Paper page
- 10.1007/BF02172145 · DOI · Paper page
- 10.1089/cap.2011.0015 · DOI · Paper page
- 10.4088/JCP.09m05933 · DOI · Paper page
- 10.1176/appi.ajp.161.6.1125 · DOI · Paper page
- McCracken JT, 2005, J Clin Psychiatry, 66, 32
- 10.1176/appi.ajp.162.6.1142 · DOI · Paper page
- 10.1007/BF00916506 · DOI
- National Institute of Mental Health, 1985, Psychopharmacol Bull, 21, 1077
- 10.1097/00004583-200203000-00014 · DOI · Paper page
- 10.1176/appi.ajp.162.7.1361 · DOI · Paper page
- 10.1097/01.chi.0000220854.79144.e7 · DOI · Paper page
- 10.1002/mrdd.20038 · DOI · Paper page
- 10.1007/s10803-006-0307-7 · DOI · Paper page
- 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
- 10.1097/01.CHI.0000046840.90931.36 · DOI
Cited by
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
An endocannabinoid-regulated basolateral amygdala–nucleus accumbens circuit modulates sociability
Folkes, O. M., Báldi, R., Kondev, V., Marcus, D. J., Hartley, N. D., Turner, B. D., Ayers, J. K., Baechle, J. J., Misra, M. P., Altemus, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131752 · Cited by 119
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Metadata
- Authors
- Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., Tierney, E., Scahill, L., Arnold, L. E., Hellings, J., Posey, D. J., Swiezy, N. B., Ghuman, J., Grados, M., Shah, B., & Vitiello, B.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-08
- Volume
- 25
- Issue
- 6
- Pages
- 482-493
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1758325167
- Cited by
- 89
- References
- 7
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.